Get the Stockscreener App
2.50
0.00%
0.00
Aprea Therapeutics Inc stock is traded at $2.50, with a volume of 4,126.
It is up +0.00% in the last 24 hours and down -35.73% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$2.50
Open:
$2.53
24h Volume:
4,126
Relative Volume:
0.14
Market Cap:
$13.59M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.6266
EPS:
-3.99
Net Cash Flow:
$-12.27M
1W Performance:
-4.58%
1M Performance:
-35.73%
6M Performance:
-28.57%
1Y Performance:
-65.28%
1-Day Range:
$2.41
$2.54
1-Week Range:
$2.41
$2.91
52-Week Range:
$2.1501
$8.8465
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
617-463-9385
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
2.50 | 13.59M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.44 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.36 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
616.37 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.03 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
267.79 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Head-To-Head Comparison: Apellis Pharmaceuticals (NASDAQ:APLS) versus Aprea Therapeutics (NASDAQ:APRE) - Defense World
Insider Buyers Lose US$92k As Aprea Therapeutics Sheds US$3.2m - Simply Wall St
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation - MSN
Aprea Therapeutics expands cancer drug patent portfolio - MSN
Ault Global (NYSEAMERICAN:DPW) Enters into Exchange Agreement with Orchid Finance LLC – Converts Outstanding Term Note for Convertible Promissory NoteThe financial landscape of Ault Global, trading under the ticker symbol DPW on the NYSE Amer - Defense World
Aprea Therapeutics Announces Update to Patent Portfolio in DNA Damage Response Cancer TherapeuticsDOYLESTOWN, PA, February 5, 2025 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) provided an update on its existing patent portf - Defense World
FDA Greenlights Aprea Therapeutics' Investigational New Drug Application for Novel Cancer Treatment - MSN
Aprea Therapeutics provides update on existing patent portfolio - Yahoo Finance
Aprea Therapeutics expands cancer drug patent portfolio By Investing.com - Investing.com South Africa
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care - The Manila Times
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics - The Manila Times
Myelodysplastic Syndrome Therapeutics Market Size in the 7MM was ~USD 2,800 Million in 2023, is expected to grow by 2034 | DelveInsight - The Globe and Mail
APRE News Today | Why did Aprea Therapeutics stock go up today? - MarketBeat
Aprea Therapeutics Discloses Unaudited Financials and Updates Corporate PresentationAprea Therapeutics, Inc. recently released an updated corporate presentation, alongside disclosing financial information as of December 31, 2024. The company shared - Defense World
StockNews.com Begins Coverage on SenesTech (NASDAQ:SNES) - Defense World
H.C. Wainwright sets target on Aprea stock, Buy rating on clinical update - MSN
HC Wainwright Reiterates Buy Rating for Aprea Therapeutics (NASDAQ:APRE) - Defense World
Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering - Yahoo Finance
Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing - MSN
Chronic Lymphocytic Leukemia Therapeutics Market Size in the 7MM is projected to grow during the forecast period 2024-2034 and estimated DelveInsight - The Globe and Mail
Lexicon Appoints Scott Coiante as Chief Financial Officer - The Manila Times
Lexicon Pharmaceuticals Names Veteran Pharma Executive Scott Coiante as New CFO - StockTitan
Short Interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) Expands By 16.4% - Defense World
HC Wainwright Reaffirms Buy Rating for Aprea Therapeutics (NASDAQ:APRE) - Defense World
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward - The Manila Times
Aprea Therapeutics Advances Novel Cancer Drug Trial with Breakthrough Dosing Strategy - StockTitan
Aprea Therapeutics Reports Q3 Financials and Advances in Clinical Trials - MSN
HC Wainwright Has Bullish Outlook for APRE FY2024 Earnings - Defense World
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher - MSN
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates - MSN
Aprea Therapeutics (NASDAQ: APRE) Announces Financial Results and Corporate Updates - Defense World
Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Health Catalyst signs definitive agreement to acquire Intraprise Health - MSN
Aprea Therapeutics Inc (APRE) Quarterly 10-Q Report - Quartz
Aprea Therapeutics Inc (APRE) Q3 2024 Earnings: Revenue Hits $0. - GuruFocus.com
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MyChesCo
Aprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International Symposium - MSN
DDR Defective Tumors Market Growth Surge: Key Players and Market - openPR
Can Aprea Therapeutics (APRE) Spring Back This Year? - RTTNews
Aprea Therapeutics (NASDAQ:APRE) Rating Reiterated by HC Wainwright - Defense World
Aprea therapeutics director sells shares worth $29,583 By Investing.com - Investing.com South Africa
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aprea Therapeutics Inc Stock (APRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gilad Oren | President/CEO |
Oct 23 '24 |
Buy |
3.92 |
500 |
1,958 |
333,395 |
| Duey Marc | Director |
Oct 16 '24 |
Buy |
4.39 |
30,000 |
131,700 |
240,113 |
| Gilad Oren | President/CEO |
Oct 15 '24 |
Buy |
2.90 |
250 |
725 |
332,895 |
| Duey Marc | Director |
Oct 14 '24 |
Buy |
2.58 |
190 |
490 |
210,113 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Oct 11 '24 |
Buy |
2.46 |
50 |
123 |
19,368 |
| Seizinger Bernd R. | Director |
Oct 11 '24 |
Buy |
2.68 |
10,000 |
26,800 |
44,730 |
| Gilad Oren | President/CEO |
Oct 14 '24 |
Buy |
2.59 |
1,000 |
2,590 |
332,645 |
| Gilad Oren | President/CEO |
Oct 10 '24 |
Buy |
2.54 |
150 |
381 |
331,645 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Oct 10 '24 |
Buy |
2.61 |
450 |
1,174 |
19,318 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Mar 13 '24 |
Buy |
7.29 |
1,010 |
7,363 |
15,503 |
1.31%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):